单纯前列腺放疗与全盆腔放疗联合或不联合近距离放疗 boost 治疗 Gleason 分级分组 5 前列腺癌:一项回顾性分析
这项多中心回顾性分析纳入 1170 例活检证实的 Gleason 分级分组 5 前列腺癌患者,比较全盆腔放疗(WPRT)与单纯前列腺放疗对生化复发无生存(bRFS)、无远处转移生存(DMFS)和前列腺癌特异性生存(PCSS)的影响。WPRT 与接受外照射+近距离放疗 boost 患者的 bRFS 改善相关(HR 0.5,95%CI 0.2-0.9,p=0.02),但在单纯外照射组无此关联,且两组 DMFS 和 PCSS 均无显著改善。
要点
- WPRT 与 EBRT+BT 组 bRFS 改善相关(HR 0.5,95%CI 0.2-0.9,p=0.02)。
- EBRT 组 WPRT 与 bRFS 无显著关联(HR 0.8,95%CI 0.6-1.2,p=0.4)。
- 两组 DMFS 和 PCSS 均未显示 WPRT 显著获益。
核心结论
- 在 GG 5 前列腺癌患者中,WPRT 与 PCSS 或 DMFS 改善无关,但在接受 EBRT+BT 的患者中与 bRFS 显著改善相关。
- 作者认为需要优化 WPRT 的策略,可能包括使用先进影像技术识别隐匿性淋巴结病变。
研究设计与样本
- 回顾性分析,纳入美国 11 个中心和挪威 1 个中心 2000 年至 2013 年治疗的 1170 例活检证实的 GG 5 前列腺癌患者。
- 734 例接受外照射放疗(EBRT),436 例接受 EBRT 联合近距离放疗 boost(EBRT+BT)。
- 采用倾向评分校正的 Cox 比例风险模型比较 bRFS、DMFS 和 PCSS。
主要发现
- EBRT 组 299 例(41%)和 EBRT+BT 组 320 例(73%)接受了 WPRT。
- EBRT 组接受 WPRT 的校正 5 年 bRFS 率为 66%,未接受 WPRT 者为 58%;EBRT+BT 组接受 WPRT 者为 88%,未接受 WPRT 者为 78%。
- 中位随访时间为 5.6 年。
- EBRT+BT 组中 WPRT 与 bRFS 改善相关(HR 0.5,95%CI 0.2-0.9,p=0.02);EBRT 组无证据表明改善(HR 0.8,95%CI 0.6-1.2,p=0.4)。
- EBRT 组 WPRT 与 DMFS(HR 1.1,95%CI 0.7-1.7,p=0.8)和 PCSS(HR 0.7,95%CI 0.4-1.1,p=0.1)无显著关联;EBRT+BT 组 WPRT 与 DMFS(HR 0.6,95%CI 0.3-1.4,p=0.2)和 PCSS(HR 0.5,95%CI 0.2-1.2,p=0.1)也无显著关联。
临床怎么用
- 作者认为需要优化 WPRT 的策略,可能包括使用先进影像技术识别隐匿性淋巴结病变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of elective whole-pelvis radiotherapy (WPRT) remains controversial. Few studies have investigated it in Gleason grade group (GG) 5 prostate cancer (PCa), known to have a high risk of nodal metastases. OBJECTIVE: To assess the impact of WPRT on patients with GG 5 PCa treated with external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT). DESIGN, SETTING, AND PARTICIPANTS: We identified 1170 patients with biopsy-proven GG 5 PCa from 11 centers in the United States and one in Norway treated between 2000 and 2013 (734 with EBRT and 436 with EBRT+BT). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Biochemical recurrence-free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific survival (PCSS) were compared using Cox proportional hazards models with propensity score adjustment. RESULTS AND LIMITATIONS: A total of 299 EBRT patients (41%) and 320 EBRT+BT patients (73%) received WPRT. The adjusted 5-yr bRFS rates with WPRT in the EBRT and EBRT+BT groups were 66% and 88%, respectively. Without WPRT, these rates for the EBRT and EBRT+BT groups were 58% and 78%, respectively. The median follow-up was 5.6yr. WPRT was associated with improved bRFS among patients treated with EBRT+BT (hazard ratio [HR] 0.5, 95% confidence interval [CI] 0.2-0.9, p=0.02), but no evidence for improvement was found in those treated with EBRT (HR 0.8, 95% CI 0.6-1.2, p=0.4). WPRT was not significantly associated with improved DMFS or PCSS in the EBRT group (HR 1.1, 95% CI 0.7-1.7, p=0.8 for DMFS and HR 0.7, 95% CI 0.4-1.1, p=0.1 for PCSS), or in the EBRT+BT group (HR 0.6, 95% CI 0.3-1.4, p=0.2 for DMFS and HR 0.5 95% CI 0.2-1.2, p=0.1 for PCSS). CONCLUSIONS: WPRT was not associated with improved PCSS or DMFS in patients with GG 5 PCa who received either EBRT or EBRT+BT. However, WPRT was associated with a significant improvement in bRFS among patients receiving EBRT+BT. Strategies to optimize WPRT, potentially with the use of advanced imaging techniques to identify occult nodal disease, are warranted. PATIENT SUMMARY: When men with a high Gleason grade prostate cancer receive radiation with external radiation and brachytherapy, the addition of radiation to the pelvis results in a longer duration of prostate-specific antigen control. However, we did not find a difference in their survival from prostate cancer or in their survival without metastatic disease. We also did not find a benefit for radiation to the pelvis in men who received radiation without brachytherapy.
引用
- Sandler KA, Cook RR, Ciezki JP, et al. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2019. PMID: 30992160. doi:10.1016/j.eururo.2019.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。